Clervonafusp alfa

克雷那芙普α

Report date: 2022/07/04 19:38:02

Base Information

Drug NameClervonafusp alfa
Drug Alias NameVAL-12213E10Fab-GAA4s3-004
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionAlpha glucosidase replacements
TargetsGlycogen
Therapy Area/IndicationsGlycogen Storage Disease Type II
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesValerion Therapeutics Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesValerion Therapeutics Llc
Active IndicationsN/A
Inactive IndicationsGlycogen Storage Disease Type II

Other Information

ATC CodeN/A
Related LinksN/A